OptimizeRx
OPRX
102 hedge funds and large institutions have $184M invested in OptimizeRx in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 37 reducing their positions, and 20 closing their positions.
4,106% more call options, than puts
Call options by funds: $10.2M | Put options by funds: $242K
3.26% less ownership
Funds ownership: 78.45% → 75.19% (-3.3%)
6% less capital invested
Capital invested by funds: $196M → $184M (-$12.2M)
7% less funds holding
Funds holding: 110 → 102 (-8)
16% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 37
40% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 20
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$12.3M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.66M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.15M |
| 4 |
State Street
Boston,
Massachusetts
|
+$985K |
| 5 |
BlackRock
New York
|
+$977K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$7.32M |
| 2 |
Millennium Management
New York
|
-$2.13M |
| 3 |
GIPM
G2 Investment Partners Management
New York
|
-$1.91M |
| 4 |
Jane Street
New York
|
-$1.85M |
| 5 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$1.82M |
OPRX Hedge Fund Activity: Q2 2023 in Review
102 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q2 2023, worth a combined $184M — down 6.2% from $196M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of OPRX and 12 opened new positions — a net loss of 8 holders — while 37 trimmed existing stakes and 31 added.
The largest buyer was First Light Asset Management, adding an estimated $12.3M. The largest seller was Casdin Capital, exiting entirely with an estimated $7.32M sold.
- 102 institutional investors held OptimizeRx (OPRX) as of Q2 2023, down from 110 in Q1 2023.
- Funds reported $184M of OptimizeRx stock for Q2 2023, down 6.2% quarter-over-quarter.
- 12 funds opened new OptimizeRx positions in Q2 2023 and 20 closed out, a net change of -8 holders.
- The largest OptimizeRx buyer in Q2 2023 was First Light Asset Management, an estimated $12.3M added.
- The largest OptimizeRx seller in Q2 2023 was Casdin Capital, an estimated $7.32M sold.
Based on aggregated 13F filings for Q2 2023.